Clinical trials: Dietary Hyperoxaluria
Healthy, Enteric Hyperoxaluria
Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria
This Phase 1, first-in-human, randomized, double-blinded, placebo controlled study is evaluating FB-001 in healthy volunteers (Part 1) and participants diagnosed with enteric hyperoxaluria (Part 2).
- Trial name
- NCT05650112
- Testing
- FB-001
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Federation Bio Inc.
Secondary Hyperoxaluria, Nephrolithiasis
A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria
Identify individuals with greater absorption of oxalate based on increase in urinary oxalate excretion in response to a controlled oxalate-rich test meal.
- Conditions
- Secondary Hyperoxaluria, Nephrolithiasis, Hyperoxaluria, Kidney Stones
- Trial name
- NCT03095885
- Testing
- Test Meal
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Allena Pharmaceuticals
Secondary Hyperoxaluria, Nephrolithiasis
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones
The purpose of this study is to evaluate the safety, tolerability, and efficacy of different doses of ALLN 177 for reducing urinary oxalate excretion in patients with secondary hyperoxaluria and recurrent kidney stones.
- Conditions
- Secondary Hyperoxaluria, Nephrolithiasis, Kidney Stones, Hyperoxaluria
- Trial name
- NCT02503345
- Testing
- ALLN-177 low dose, ALLN-177 mid dose, ALLN-177 high dose
- Where
- 16 sites in United States
- Volunteers
- 32 people
- Sponsor
- Allena Pharmaceuticals
Secondary Hyperoxaluria, Nephrolithiasis
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days
Evaluate the safety, tolerability, and efficacy of 28 days of treatment with ALLN-177 for reducing urinary oxalate excretion in patients with secondary hyperoxaluria and kidney stones.
- Conditions
- Secondary Hyperoxaluria, Nephrolithiasis, Hyperoxaluria, Kidney Stones
- Trial name
- NCT02547805
- Testing
- ALLN-177
- Where
- 22 sites in United States
- Volunteers
- 66 people
- Sponsor
- Allena Pharmaceuticals